⮝ Full datasets listing

PXD054900

PXD054900 is an original dataset announced via ProteomeXchange.

Dataset Summary
TitleLongitudinal Proteomic Fingerprinting in CSF of Nusinersen-Treated Patients with 5q-Associated Spinal Muscular Atrophy
DescriptionAbstract Introduction: 5q-associated spinal muscular atrophy (SMA) is a motor neuron disease causing progressive alpha motor neuron degeneration, muscle atrophy, and weakness. Intrathecal therapy with the antisense oligonucleotide Nusinersen modifies the disease course. However, biomarkers for understanding underlying molecular pathomechanisms and monitoring therapy are not yet known. Methods: 130 cerebrospinal fluid (CSF) samples from 24 SMA type 2 and 3 adult patients were collected over 3.5 years and CSF proteome was using mass spectrometry (MS). By employing two complementary MS protein quantification methods, label-free quantification (LFQ) and tandem mass tag (TMT) isotopic labeling, specific protein patterns reflecting changes in the CSF in the context of nusinersen therapy were identified. These results were combined with cellular and metabolic profiles. Results: Nusinersen therapy led to a median motor function improvement of 2.2 Hammersmith Functional Motor Scale Expanded points after 10 months and 2.6 points after 34 months. Albumin concentration and albumin quotient (CSF/serum) increased, as did the number of macrophages in the CSF under nusinersen therapy. Albumin, glucose, and lactate concentrations were inversely correlated with clinical improvement. MS analysis of CSF identified 1,674 (TMT) and 441 (LFQ) proteins. Protein profiles associated with clinical improvement reflected the reconstitution of neuronal circuits. Additionally, clinical improvement was associated with reduced humoral mediators of the immune response such as complement factors and immunoglobulins and cellular mediators such as lymphocytes. Discussion: Our multi-proteomic analysis provides new insights into the pathobiology of SMA and defines potential biomarker profiles in CSF for the disease course under nusinersen therapy.
HostingRepositoryPRIDE
AnnounceDate2025-05-07
AnnouncementXMLSubmission_2025-05-07_02:25:42.401.xml
DigitalObjectIdentifier
ReviewLevelPeer-reviewed dataset
DatasetOriginOriginal dataset
RepositorySupportUnsupported dataset by repository
PrimarySubmitterUwe Warnken
SpeciesList scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationListTMT6plex-126 reporter+balance reagent acylated residue; monohydroxylated residue; deamidated residue; iodoacetamide derivatized residue
InstrumentQ Exactive
Dataset History
RevisionDatetimeStatusChangeLog Entry
02024-08-14 14:19:17ID requested
12025-05-07 02:25:43announced
Publication List
10.1007/s00415-025-12984-7;
Cebulla G, Hai L, Warnken U, G, ü, ng, ö, r C, Hoffmann DC, Korporal-Kuhnke M, Wildemann B, Wick W, Kessler T, Weiler M, Long-term CSF responses in adult patients with spinal muscular atrophy type 2 or 3 on treatment with nusinersen. J Neurol, 272(4):270(2025) [pubmed]
Keyword List
submitter keyword: cerebrospinal fluid, TMT, nusinersen,spinal muscle atrophy, SMA, CSF
Contact List
Prof. Dr. med. Wolfgang Wick
contact affiliationClinical Cooperation Unit Neurooncology B320 German Cancer Research Center Heidelberg
contact emailw.wick@dkfz-heidelberg.de
lab head
Uwe Warnken
contact affiliationGerman Cancer Research Center Heidelberg, Clinical Cooperation Unit Neurooncology B320
contact emailu.warnken@dkfz.de
dataset submitter
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/05/PXD054900
PRIDE project URI
Repository Record List
[ + ]